MOGS
Mannosyl-oligosaccharide glucosidase
Also known as: CWH41, DER7, GCS1, MOGS_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13724
- Gene
- MOGS
- Ensembl
- ENSG00000115275
- Chromosome
- 2
- Canonical length
- 837 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Endoplasmic reticulum
OverviewNCBI Gene
This gene encodes the first enzyme in the N-linked oligosaccharide processing pathway. The enzyme cleaves the distal alpha-1,2-linked glucose residue from the Glc(3)-Man(9)-GlcNAc(2) oligosaccharide precursor. This protein is located in the lumen of the endoplasmic reticulum. Defects in this gene are a cause of type IIb congenital disorder of glycosylation (CDGIIb). Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2009]
Canonical amino-acid sequenceUniProt
837 residues, UniProt reviewed canonical sequence.
>Q13724|MOGS
1 MARGERRRRA VPAEGVRTAE RAARGGPGRR DGRGGGPRST AGGVALAVVV LSLALGMSGR
61 WVLAWYRARR AVTLHSAPPV LPADSSSPAV APDLFWGTYR PHVYFGMKTR SPKPLLTGLM
121 WAQQGTTPGT PKLRHTCEQG DGVGPYGWEF HDGLSFGRQH IQDGALRLTT EFVKRPGGQH
181 GGDWSWRVTV EPQDSGTSAL PLVSLFFYVV TDGKEVLLPE VGAKGQLKFI SGHTSELGDF
241 RFTLLPPTSP GDTAPKYGSY NVFWTSNPGL PLLTEMVKSR LNSWFQHRPP GAPPERYLGL
301 PGSLKWEDRG PSGQGQGQFL IQQVTLKIPI SIEFVFESGS AQAGGNQALP RLAGSLLTQA
361 LESHAEGFRE RFEKTFQLKE KGLSSGEQVL GQAALSGLLG GIGYFYGQGL VLPDIGVEGS
421 EQKVDPALFP PVPLFTAVPS RSFFPRGFLW DEGFHQLVVQ RWDPSLTREA LGHWLGLLNA
481 DGWIGREQIL GDEARARVPP EFLVQRAVHA NPPTLLLPVA HMLEVGDPDD LAFLRKALPR
541 LHAWFSWLHQ SQAGPLPLSY RWRGRDPALP TLLNPKTLPS GLDDYPRASH PSVTERHLDL
601 RCWVALGARV LTRLAEHLGE AEVAAELGPL AASLEAAESL DELHWAPELG VFADFGNHTK
661 AVQLKPRPPQ GLVRVVGRPQ PQLQYVDALG YVSLFPLLLR LLDPTSSRLG PLLDILADSR
721 HLWSPFGLRS LAASSSFYGQ RNSEHDPPYW RGAVWLNVNY LALGALHHYG HLEGPHQARA
781 AKLHGELRAN VVGNVWRQYQ ATGFLWEQYS DRDGRGMGCR PFHGWTSLVL LAMAEDYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MOGS can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 40 nTPM
Expression across tissuesHPA
Tissue
- duodenum: 40 nTPM
- placenta: 33 nTPM
- small intestine: 28 nTPM
- salivary gland: 26 nTPM
- pancreas: 26 nTPM
- skin: 24 nTPM
Single-cell type
- late spermatids: 378 nCPM
- early spermatids: 80 nCPM
- syncytiotrophoblasts: 71 nCPM
- extravillous trophoblasts: 69 nCPM
- plasma cells: 67 nCPM
- breast lactating cells: 63 nCPM
Immune cell
- NK-cell: 8.4 nTPM
- basophil: 6.8 nTPM
- non-classical monocyte: 3.9 nTPM
- MAIT T-cell: 3.3 nTPM
- T-reg: 3.3 nTPM
- gdT-cell: 2.6 nTPM
Brain region
- pons: 10 nTPM
- white matter: 9.9 nTPM
- medulla oblongata: 9.1 nTPM
- spinal cord: 8.9 nTPM
- choroid plexus: 8.7 nTPM
- hypothalamus: 8.4 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MOGS.
Disease | AllUniProt
Conditions MOGS is implicated in, by any mechanism.
- Type IIb congenital disorder of glycosylation (CDGIIb) MIM:606056
Disease | GeneticClinVar
38 pathogenic / likely-pathogenic of 628 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- MOGS-congenital disorder of glycosylation
- MOGS-related disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.96
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.66
- DepMap mean gene effect
- -0.2
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- oligosaccharide metabolic process
- protein folding
- protein N-linked glycosylation
- viral protein processing
Molecular functions
- Glc3Man9GlcNAc2 oligosaccharide glucosidase activity
- glucosidase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Six-hairpin glycosidase superfamily
- Six-hairpin glycosidase-like superfamily
- Glycoside hydrolase family 63
- Glycosyl hydrolase family 63, C-terminal
- Glycosyl hydrolase family 63, N-terminal
- Glycosyl hydrolase family 63, N-terminal domain superfamily
- Glycosyl hydrolase family 63 C-terminal domain
- Glycosyl hydrolase family 63 N-terminal domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MOGS in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MOGS as an antibody target. Whether an autoantibody or antibody against MOGS could matter depends on whether native MOGS is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MOGS is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MOGS as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...